ESSA Pharma Inc.
EPIX
$0.07
Change (1 day)
$11.67
Year High
$1.40
Year Low
Categories
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
ESSA Pharma Inc. (EPIX) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 135.06 K | -33,621,584 | 3.5 M | 149.12 M | 148.8 M |
| 2022 | 6.21 K | -56,866,166 | 2.39 M | 169.51 M | 169.51 M |
| 2021 | 489.01 K | -137,494,054 | 4.16 M | 198.17 M | 197.6 M |
| 2020 | 309.54 K | -56,261,906 | 1.33 M | 80.58 M | 80.58 M |
| 2019 | 360.8 K | -49,614,045 | 5.59 M | 54.77 M | 54.77 M |